196170.KQ
SellFallen FavouriteALTEOGEN Inc. · Healthcare · South Korea · $16.2B · Avg Vol: $99M/d
Fallen Favourite: A good business that is expensive and falling. Wait for the price to catch up.
ABOUT ALTEOGEN INC.
Read
ALTEOGEN Inc. is a South Korean clinical-stage biotechnology company specializing in long-acting biobetters and proprietary drug delivery technologies, notably its ALT-B4 subcutaneous injection platform. The company's competitive moat is secured by its extensive patent portfolio and high-value licensing agreements with global pharmaceutical giants seeking to convert intravenous drugs to subcutaneous forms. Alteogen operates as a high-growth, technology-enabling leader in the global biologics sector.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.8B | 96.5B | 102.9B | 215.9B | 95.7% | 248.4B | 468.9B | — | 117.2% |
| EPS (KRW) | -159.00 | -65.00 | 1,172 | 2,653 | 126.4% | 2,595 | 4,234 | 5,452 | 43.3% |
| Shares | 51.5M | 53.0M | 53.3M | 53.5M | +3.9% | 69.6M | — | — | — |
| Debt | 4.3B | 1.7B | 11.8B | 7.1B | 17.7% | 6.9B | — | — | — |
| Equity | 148.8B | 148.1B | 273.6B | 445.2B | 44.1% | — | — | — | — |
| Op CF | -17.9B | -7.8B | 53.0B | 124.1B | 134.0% | 95.5B | — | — | — |
| Inv CF | 50.2B | -9.3B | -107.8B | -231.1B | — | — | — | — | — |
| Fin CF | 2.9B | 1.7B | 43.3B | 155.6B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 196170.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 196170.KQ | ALTEOGEN Inc.(you) | $16.2B | 34 | Sell |
| 068270.KS | Celltrion, Inc. | $31.4B | 45 | Hold |
| 207940.KS | Samsung Biologics Co.,Ltd. | $50.2B | 52 | Hold |
| 0126Z0.KS | Samsung Epis Holdings Co., Ltd. | $6.8B | 5 | Strong Sell |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $5.0B | 61 | Hold |
| 302440.KS | SK bioscience Co.,Ltd. | $2.2B | 14 | Strong Sell |
| 028300.KQ | HLB Co., Ltd. | $3.5B | 1 | Strong Sell |
| 298380.KQ | ABL Bio Inc. | $3.1B | 1 | Strong Sell |
| 141080.KQ | LigaChem Biosciences Inc. | $2.7B | 3 | Strong Sell |
| 310210.KQ | Voronoi, Inc. | $2.3B | 1 | Strong Sell |
Peer medians: ROE 0.0% · P/E 16.4x · Gross margin 42.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.